Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Moderate Buy” by Analysts

Cryoport, Inc. (NASDAQ:CYRX) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $12.29.

A number of brokerages have recently issued reports on CYRX. UBS Group raised their price target on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Roth Mkm lowered their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th.

Insider Transactions at Cryoport

In related news, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the transaction, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at $4,764,649.47. This represents a 6.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now owns 59,497 shares of the company’s stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CYRX. Rhumbline Advisers increased its holdings in shares of Cryoport by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock valued at $443,000 after purchasing an additional 2,086 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Cryoport during the second quarter worth $92,000. XTX Topco Ltd purchased a new stake in Cryoport during the second quarter worth $198,000. Marshall Wace LLP acquired a new position in shares of Cryoport during the 2nd quarter worth $282,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Cryoport in the 2nd quarter valued at about $378,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Price Performance

NASDAQ:CYRX opened at $8.16 on Wednesday. The stock has a 50 day moving average of $7.68 and a two-hundred day moving average of $7.90. Cryoport has a 12 month low of $5.32 and a 12 month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm has a market cap of $403.35 million, a P/E ratio of -2.41 and a beta of 1.58.

Cryoport (NASDAQ:CYRX) last released its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.23. The business had revenue of $56.66 million for the quarter, compared to analyst estimates of $58.13 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period last year, the company posted ($0.31) EPS. On average, analysts expect that Cryoport will post -0.99 earnings per share for the current fiscal year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.